ASCO Updates Clinical Guidelines for HER2-Negative Breast Cancer

The guidelines suggest various treatment options available, following consideration of the patient's status and preference.

Methods A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1993 through to current was completed. Outcomes of interest included survival, progression-free survival, response, quality of life, and adverse effects. Guideline recommendations were evidence based and were agreed on by the Expert Panel via consensus.

Results Seventy-nine studies met the inclusion criteria, comprising 20 systematic reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and subsequent treatment. These trials form the evidence base for the guideline recommendations.

Link to the article: http://bit.ly/1qo60AD

Source: Journal of Clinical Oncology

To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)— negative (or unknown) advanced breast cancer.